Dr Cedric Cui

Postdoctoral Research Fellow

School of Biomedical Sciences

s.cui@uq.edu.au

Dr Cui joined the Neuroinflammation Lab in late 2018 as a PhD student, under the supervision of Professor Trent Woodruff. His research project focused on the preclinical development of C5aR1 antagonists for the treatment of various inflammatory diseases, including inflammatory bowel disease (IBD). In 2023, he was appointed as a postdoctoral research fellow under the supervision of Dr John Lee. His current project focuses on investigating new therapeutics for neurodegenerative diseases. Dr Cui’s recent experience includes working with LC-MS/MS, QdToF, and timsToF fleX-MALDI-2, for conducting pharmacokinetics, neurotransmitter, and spatial metabolomic and lipidomic studies.

Publications

Journal Articles (8)

Thesis (1)

Journal Articles

Xu, Weizhi, Kumar, Vinod, Cui, Cedric S., Li, Xaria X., Whittaker, Andrew K., Xu, Zhi Ping, Smith, Maree T., Woodruff, Trent M. and Han, Felicity Y (2022). Success in navigating hurdles to oral delivery of a bioactive peptide complement antagonist through use of nanoparticles to increase bioavailability and in vivo efficacy. Advanced Therapeutics, 5 (12) 2200109, 2200109. doi: 10.1002/adtp.202200109

Cui, Cedric S., Kumar, Vinod, Gorman, Declan M., Clark, Richard J., Lee, John D. and Woodruff, Trent M. (2021). In vivo pharmacodynamic method to assess complement C5a receptor antagonist efficacy. ACS Pharmacology and Translational Science, 5 (1) acsptsci.1c00227, 41-51. doi: 10.1021/acsptsci.1c00227

Xu, Weizhi, Maqbool, Faheem, Kumar, Vinod, Falconer, James R., Cui, Cedric S., Woodruff, Trent M., Borges, Karin, Whittaker, Andrew K., Smith, Maree T. and Han, Felicity Y. (2021). Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. Drug Delivery and Translational Research, 12 (10), 2518-2526. doi: 10.1007/s13346-021-01093-3

Gorman, Declan M., Li, Xaria X., Payne, Colton D., Cui, Cedric S., Lee, John D., Rosengren, K. Johan, Woodruff, Trent M. and Clark, Richard J. (2021). Development of synthetic human and mouse C5a: application to binding and functional assays in vitro and in vivo. ACS Pharmacology and Translational Science, 4 (6) acsptsci.1c00199, 1808-1817. doi: 10.1021/acsptsci.1c00199

Gorman, Declan M., Li, Xaria X., Lee, John D., Fung, Jenny N., Cui, Cedric S., Lee, Han Siean, Rolfe, Barbara E., Woodruff, Trent M. and Clark, Richard J. (2021). Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. Journal of Medicinal Chemistry, 64 (22) acs.jmedchem.1c01174, 16598-16608. doi: 10.1021/acs.jmedchem.1c01174

Pandey, Shubhi, Kumari, Punita, Baidya, Mithu, Kise, Ryoji, Cao, Yubo, Dwivedi-Agnihotri, Hemlata, Banerjee, Ramanuj, Li, Xaria X., Cui, Cedric S., Lee, John D., Kawakami, Kouki, Maharana, Jagannath, Ranjan, Ashutosh, Chaturvedi, Madhu, Jhingan, Gagan Deep, Laporte, Stéphane A., Woodruff, Trent M., Inoue, Asuka and Shukla, Arun K. (2021). Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors. Molecular Cell, 81 (22), 4605-4621.e11. doi: 10.1016/j.molcel.2021.09.007

Han, Felicity Y., Xu, Weizhi, Kumar, Vinod, Cui, Cedric S., Li, Xaria, Jiang, Xingyu, Woodruff, Trent M., Whittaker, Andrew K. and Smith, Maree T. (2021). Optimisation of a microfluidic method for the delivery of a small peptide. Pharmaceutics, 13 (9) 1505, 1505. doi: 10.3390/pharmaceutics13091505

Chakraborty, Rituparna, Chandra, Janin, Cui, Shuai, Tolley, Lynn, Cooper, Matthew A., Kendall, Mark and Frazer, Ian H. (2017). CD8+ lineage dendritic cells determine adaptive immune responses to inflammasome activation upon sterile skin injury. Experimental Dermatology, 27 (1), 71-79. doi: 10.1111/exd.13436

Thesis

Cui, Shuai (2022). Preclinical development of complement C5aR1 antagonists for the treatment of inflammatory bowel disease. PhD Thesis, School of Biomedical Sciences, The University of Queensland. doi: 10.14264/3a8be04